The ALDH2 and DRD2/ANKK1 genes interacted in bipolar II but not bipolar i disorder

Pharmacogenetics and Genomics

Volumn 20, Issue 8, 2010, Pages 500-506

  Lee, Sheng Yu ^a,b   Chen, Shiou Lan ^a   Chang, Yun Hsuan ^a,b   Chen, Shih Heng ^a   Chu, Chun Hsieh ^a   Huang, San Yuan ^c   Tzeng, Nian Sheng ^c   Wang, Chen Lin ^a   Lee, I Hui ^a   Yeh, Tzung Lieh ^a   Yang, Yen Kuang ^a   Lu, Ru Band ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 2; DOPAMINE 2 RECEPTOR; PROTEIN; PROTEIN ANKK1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE INTERACTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 77954955404     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833caa2b     Document Type: Article

References (95)

1. Keck PE Jr, McElroy SL, Arnold LM. Bipolar disorder. Med Clin North Am 2001; 85:645-661, ix.
2. Osby U, Brandt L, Correia N, Ekbom A, Sparén P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58:844-850.
3. Akiskal HS. Validating 'hard' and 'soft' phenotypes within the bipolar spectrum: continuity or discontinuity? J Affect Disord 2003; 73:1-5.
4. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Maser J, Rice JA, et al. The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders? J Affect Disord 2003; 73:19-32.
5. Kelsoe JR. Arguments for the genetic basis of the bipolar spectrum. J Affect Disord 2003; 73:183-197.
6. McMahon FJ, Simpson SG, McInnis MG, Badner JA, MacKinnon DF, DePaulo JR. Linkage of bipolar disorder to chromosome 18q and the validity of bipolar II disorder. Arch Gen Psychiatry 2001; 58:1025-1031.
7. Vieta E, Gasto C, Otero A, Nieto E, Vallejo J. Differential features between bipolar I and bipolar II disorder. Compr Psychiatry 1997; 38:98-101.
8. Pallanti S, Quercioli L, Pazzagli A, Rossi A, Dell'Osso L, Pini S, et al. Awareness of illness and subjective experience of cognitive complaints in patients with bipolar I and bipolar II disorder. Am J Psychiatry 1999; 156:1094-1096.
9. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Leon AC, Solomon DA, et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry 2005; 62:1322-1330.
10. Rihmer Z, Angst A. Mood disorders: epidemiology. In: Sadock BJ, Sadock VA, editors. Comprehensive textbook of psychiatry. 8th ed. Baltimore: Lippincott Williams & Wilkins; 2004.
11. Akiskal HS. The bipolar spectrum: research and clinical perspectives. Encephale 1995; 21:3-11.
12. Akiskal HS, Pinto O. The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr Clin North Am 1999; 22:517-534, vii.
13. Angst J, Gamma A, Benazzi F, Ajdacic V, Eich D, Rossler W. Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J Affect Disord 2003; 73:133-146.
14. Berk M, Dodd S. Bipolar II disorder: a review. Bipolar Disord 2005; 7:11-21.
15. Kendler KS, Pedersen NL, Neale MC, Mathe AA. A pilot Swedish twin study of affective illness including hospital-and population-ascertained subsamples: results of model fitting. Behav Genet 1995; 25:217-232.
16. McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry 2003; 60:497-502.
17. Coryell W, Endicott J, Reich T, Andreasen N, Keller M. A family study of bipolar II disorder. Br J Psychiatry 1984; 145:49-54.
18. Sadovnick AD, Remick RA, Lam R, Zis AP, Yee IM, Huggins MJ, et al. Mood Disorders Service Genetic Database: morbidity risks for mood disorders in 3942 first-degree relatives of 671 index cases with single depression, recurrent depression, bipolar I or bipolar II. Am J Med Genet 1994; 54:132-140.
19. Brugue E, Vieta E. Atypical antipsychotics in bipolar depression: Neurobiological basis and clinical implications. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:275-282.
20. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007; 64:327-337.
21. Gershon AA, Vishne T, Grunhaus L. Dopamine D2-like receptors and the antidepressant response. Biol Psychiatry 2007; 61:145-153.
22. Silverstone T, Romans-Clarkson S. Bipolar affective disorder: causes and prevention of relapse. Br J Psychiatry 1989; 154:321-335.
23. Gerner RH, Post RM, Bunney WE. Dopaminergic mechanism in mania. Am J Psychiatry 1996; 133:1177-1180.
24. Nierenberg AA, Dougherty D, Rosenbaum JF. Dopaminergic agents and stimulants as antidepressant augmentation strategies. J Clin Psychiatry 1998; 59 (Suppl 5):60-63.
25. Taylor AE, Saint-Cyr JA. Depression in Parkinson's disease: reconciling physiological and psychological perspectives. J Neuropsychiatry Clin Neurosci 1990; 2:92-98.
26. Saint-Cyr JA, Taylor AE, Lang AE. Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology 1993; 43:S47-S52.
27. Mann JJ, Kapur S. A dopaminergic hypothesis of major depression. Clin Neuropharmacol 1995; 18(Suppl 1):S57-S67.
28. Pohjalainen T, Rinne JO, Nagren K, Lehikoinen P, Anttila K, Syvalahti EK, et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998; 3:256-260.
29. Jönsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P, et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999; 4:290-296.
30. Ritchie T, Noble EP. Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 2003; 28:73-82.
31. Souery D, Lipp O, Mahieu B, Mendelbaum K, De Martelaer V, Van Broeckhoven C, et al. Association study of bipolar disorder with candidate genes involved in catecholamine neurotransmission: DRD2, DRD3, DAT1, and TH genes. Am J Med Gen 1996; 67:551-555.
32. Kirov G, Jones I, McCandless F, Craddock N, Owen MJ. Family-based association studies of bipolar disorder with candidate genes involved in dopamine neurotransmission: DBH, DAT1, COMT, DRD2, DRD3 and DRD5. Mol Psychiatry 1999; 4:558-565.
33. Li T, Liu X, Sham PC, Aitchison KJ, Cai G, Arranz MJ, et al. Association analysis between dopamine receptor genes and bipolar affective disorder. Psychiatry Res 1999; 86:193-201.
34. Furlong RA, Coleman TA, Ho L, Rubinsztein JS, Walsh C, Paykel ES, et al. No association of a functional polymorphism in the dopamine D2 receptor promoter region with bipolar or unipolar affective disorders. Am J Med Genet 1998; 81:385-387.
35. Stöber G, Jatzke S, Heils A, Jungkunz G, Knapp M, Mössner R, et al. Insertion/deletion variant (-141C Ins/Del) in the 5 regulatory region of the dopamine D2 receptor gene: lack of association with schizophrenia and bipolar affective disorder. Short communication. J Neural Transm 1998; 105:101-109.
36. Leszczyńska-Rodziewicz A, Hauser J, Dmitrzak-Weglarz M, Skibińka M, Czerski P, Zakrzewska A, et al. Lack of association between polymorphisms of dopamine receptors, type D2, and bipolar affective illness in a Polish population. Med Sci Monit 2005; 11:CR289-CR295.
37. Cesura AM, Pletscher A. The new generation of monoamine oxidase inhibitors. Prog Drug Res 1992; 38:171-297.
38. Westerink BH, de Vries JB. On the origin of dopamine and its metabolite in predominantly noradrenergic innervated brain areas. Brain Res 1985; 330:164-166.
39. Lamensdorf I, Eisenhofer G, Harvey-White J, Nechustan A, Kirk K, Kopin IJ. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain Res 2000; 868:191-201.
40. Keung WM, Vallee BL. Daidzin: a potent, selective inhibitor of human mitochondrial aldehyde dehydrogenase. Proc Natl Acad Sci USA 1993; 90:1247-1251.
41. Crabb DW, Edenberg HJ, Bosron WF, Li TK. Genotypes for aldehyde dehydrogenase deficiency and alcohol sensitivity. The inactive ALDH2(2) allele is dominant. J Clin Invest 1989; 83:314-316.
42. Yoshida A, Hsu LC, Yasunami M. Genetics of human alcohol-metabolizing enzymes. Prog Nucleic Acid Res Mol Biol 1991; 40:255-287.
43. Wurst FM, Tabakoff B, Alling C, Aradottir S, Wiesbeck GA, Muller-Spahn F, et al. World Health Organization/International Society for Biomedical Research on Alcoholism study on state and trait markers of alcohol use and dependence: back to the future. Alcohol Clin Exp Res 2005; 29:1268-1275.
44. Agarwal DP, Goedde HW. Pharmacogenetics of alcohol metabolism and alcoholism. Pharmacogenetics 1992; 2:48-62.
45. Chen CC, Lu RB, Chen YC, Wang MF, Chang YC, Li TK, et al. Interaction between the functional polymorphisms of the alcohol-metabolism genes in protection against alcoholism. Am J Hum Genet 1999; 65:795-807.
46. Thomasson HR, Edenberg HJ, Crabb DW, Mai XL, Jerome RE, Li TK, et al. Alcohol and aldehyde dehydrogenase genotypes and alcoholism in Chinese men. Am J Hum Genet 1991; 48:677-681.
47. Lee HC, Lee HS, Jung SH, Yi SY, Jung HK, Yoon JH, et al. Association between polymorphisms of ethanol-metabolizing enzymes and susceptibility to alcoholic cirrhosis in a Korean male population. J Korean Med Sci 2001; 16:745-750.
48. Nakamura K, Iwahashi K, Matsuo Y, Miyatake R, Ichikawa Y, Suwaki H. Characteristics of Japanese alcoholics with the atypical aldehyde dehydrogenase 2*2. I. A comparison of the genotypes of ALDH2, ADH2, ADH3, and cytochrome P-4502E1 between alcoholics and nonalcoholics. Alcohol Clin Exp Res 1996; 20:52-55.
49. Smith EN, Bloss CS, Badner JA, Barrett T, Belmonte PL, Berrettini W, et al. Genome-wide association study of bipolar disorder in European American and African American individuals. Mol Psychiatry 2009; 14:755-763.
50. Li X, Zhang J, Wang Y, Ji J, Yang F, Wan C, et al. Association study on the NAPG gene and bipolar disorder in the Chinese Han population. Neurosci Lett 2009; 457:159-162.
51. Craddock N, Sklar P. Genetics of bipolar disorder: successful start to a long journey. Trends Genet 2009; 25:99-105.
52. Carlson CS, Eberle MA, Kruglyak L, Nickerson DA. Mapping complex disease loci in whole-genome association studies. Nature 2004; 429:446-452.
53. Urata T, Takahashi N, Hakamata Y, Iijima Y, Kuwahara N, Ozaki N, et al. Gene-gene interaction analysis of personality traits in a Japanese population using an electrochemical DNA array chip analysis. Neurosci Lett 2007; 414:209-212.
54. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978; 35:837-844.
55. Huang SY, Lin WW, Ko HC, Lee JF, Wang TJ, Chou YH, et al. Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. Alcohol Clin Exp Res 2004; 28:374-384.
56. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSM-IV-TR). 4th edition. Washington, DC: American Psychiatric Association; 2000.
57. Spitzer RL, Endicott J, Williams JB. Research diagnostic criteria. Arch Gen Psychiatry 1979; 36:1381-1383.
58. Akiskal HS, Djenderedjian AM, Rosenthal RH, Khani MK. Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group. Am J Psychiatry 1977; 134:1227-1233.
59. Akiskal HS, Rosenthal RH, Rosenthal TL, Kashgarian M, Khani MK, Puzantian VR. Differentiation of primary affective illness from situational, symptomatic, and secondary depressions. Arch Gen Psychiatry 1979; 36:635-643.
60. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998; 50:143-151.
61. Benazzi F. Is 4 days the minimum duration of hypomania in bipolar II disorder? Eur Arch Psychiatry Clin Neurosci 2001; 251:32-34.
62. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60:261-269.
63. Grandy DK, Zhang Y, Civelli O. PCR detection of the TaqA RFLP at the DRD2 locus. Hum Mol Genet 1993; 2:2197.
64. Dandré F, Cassaigne A, Iron A. The frequency of the mitochondrial aldehyde dehydrogenase I2 (atypical) allele in Caucasian, Oriental and African Black populations determined by the restriction profile of PCR-amplified DNA. Mol Cell Probes 1995; 9:189-193.
65. Keung WM, Vallee BL. Daidzin and its antidipsotropic analogs inhibit serotonin and dopamine metabolism in isolated mitochondria. Proc Natl Acad Sci USA 1998; 95:2198-2203.
66. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 1991; 48:648-654.
67. Regier DA, Farmer ME, Raw DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264:2511-2518.
68. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997; 54:313-321.
69. Sonne SC, Brady KT. Substance abuse and bipolar comorbidity. Psychiatr Clin North Am 1999; 22:609-627, ix.
70. Strakowski SM, DelBello MP, Fleck DE, Arndt S. The impact of substance abuse on the course of bipolar disorder. Biol Psychiatry 2000; 48:477-485.
71. Vornik LA, Brown ES. Management of comorbid bipolar disorder and substance abuse. J Clin Psychiatry 2006; 67 (Suppl 7):24-30.
72. Brady KT, Lydiard R. Bipolar affective disorder and substance abuse. J Clin Psychopharmacol 1992; 12:17S-22S.
73. Sonne SC, Brady KT, Morton WA. Substance abuse and bipolar affective disorder. J Nerv Ment Dis 1994; 182:349-352.
74. Helzer JE, Pryzbeck TR. The co-occurrence of alcoholism with other psychiatric disorders in the general population and its impact on treatment. J Stud Alcohol 1988; 49:219-224.
75. Strakowski SM, DelBello MP. The co-occurrence of bipolar and substance use disorders. Clin Psychol Rev 2000; 20:191-206.
76. Keck PE Jr, McElroy SL, Strakowski SM, West SA, Sax KW, Hawkins JM, et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998; 155:646-652.
77. Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet 2003; 116:103-125.
78. Jocham G, Klein TA, Neumann J, von Cramon DY, Reuter M, Ullsperger M. Dopamine DRD2 polymorphism alters reversal learning and associated neural activity. J Neurosci 2009; 29:3695-3704.
79. Egaña LA, Cuevas RA, Baust TB, Parra LA, Leak RK, Hochendoner S, et al. Physical and functional interaction between the dopamine transporter and the synaptic vesicle protein synaptogyrin-3. J Neurosci 2009; 29:4592-4604.
80. Padmanabhan S, Prasad BM. Sustained depolarization decreases calcium/calmodulin-dependent protein kinase II activity and gene expression in dopamine neurons. Neuroscience 2009; 163:277-285.
81. Peng X, Tehranian R, Dietrich P, Stefanis L, Perez RG. Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J Cell Sci 2005; 118:3523-3530.
82. Tehranian R, Montoya SE, Van Laar AD, Hastings TG, Perez RG. Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells. J Neurochem 2006; 99:1188-1196.
83. Zhang D, Kanthasamy A, Yang Y, Anantharam V, Kanthasamy A. Protein Kinas C delta negatively regulates tyrosine hydoxylase activity and dopamine synthesis by enhancing protein phosphatase-2A activity in dopaminergic neurons. J Neurosci 2007; 27:5349-5362.
84. Wang J, Lou H, Pedersen CJ, Smith AD, Perez RG. 14-3-3zeta contributes to tyrosine hydroxylase activity in MN9D cells: localization of dopamine regulatory proteins to mitochondria. J Biol Chem 2009; 284:14011-14019.
85. Cumming P, Brown E, Damsma G, Fibiger H. Formation and clearance of interstitial metabolites of dopamine and serotonin in the rat striatum: an in vivo microdialysis study. J Neurochem 1992; 59:1905-1914.
86. Tokunaga K, Ishikawa K. Evidence for different sites of monoamine oxidase and catechol-O-methyltransferase in the striatum. Brain Res 1992; 575:164-166.
87. Beyer JL, Krishnan KR. Volumetric brain imaging findings in mood disorders. Bipolar Disord 2002; 4:89-104.
88. Drevets WC, Price JL, Simpson JR Jr, Todd RD, Reich T, Vannier M, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997; 386:824-827.
89. Stoll AL, Renshaw PF, Yurgelun-Todd DA, Cohen BM. Neuroimaging in bipolar disorder: what have we learned? Biol Psychiatry 2000; 48:505-517.
90. Chen PS, Peng GS, Li G, Yang S, Lu RB, Gean PW, et al. Valproate induces GDNF in astrocyte and exhibits neurotrophic and neuroprotective effects in midbrain dopaminergic neurons. Mol Psychiatry 2006; 11:1116-1125.
91. Peng GS, Li G, Tzeng NS, Chen PS, Chuang DM, Hsu YD, et al. Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res Mol Brain Res 2005; 134:162-169.
92. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry 2000; 48:813-829.
93. Bauer M, Alda M, Priller J, Young LT; International Group For The Study Of Lithium Treated Patients (IGSLI). Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry 2003; 36:S250-S254.
94. Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS. 3,4- Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Res 2003; 989:205-213.
95. Coryell W, Endicott J, Maser JD, Keller MB, Leon AC, Akiskal HS. Long-term stability of polarity distinctions in the affective disorders. Am J Psychiatry 1995; 152:385-390.